Brand & Product Security

From November 2023, the Drug Supply Chain Security Act requires healthcare manufacturers, distributors, providers, and dispensers to exchange the serialized item-level product information that has been collected, standardized, and digitized. Hitting this deadline hinges on intensive collaboration between manufacturers and their supply chain partners that must begin now

More biologic-based therapies translates into more cold chain activity. As yet, new cellular and genetic therapies are a minute part of the overall market.

A 2017 postponement makes 2018 the key year for serializing US products; authentication makes a comeback, and cargo security goes digital

Patient support (hub) services rise in lockstep with specialty pharmaceutical launches

Drug-based therapies for opioid dependency gain acceptance and reimbursement

New industry entrants aim at expanding patient volumes even while drug compounding limits some therapy classes

Vendors and service providers scramble to serve a growing market

Pharma spends heavily to secure its supply chain, while politicians bring out the re-importation topic

More volumes of more valuable products drive growth

A silver anniversary with golden opportunities

Meeting the compliance deadlines of the Drug Supply Chain Security Act has the attention of many in biopharma product and brand security

For specialty pharmaceuticals, the connection between manufacturer, payer and patient is the rising crop of hub services

When entering the specialty pharmaceuticals arena, manufacturers need to evaluate the capabilities of their channel partners carefully

HDMA's fourth edition polling its members and manufacturers, on trends in specialty distribution

Serialization systems are going into operation around the world, but cross-industry collaboration awaits new legislation

With partial support from manufacturers themselves, home health services are emerging as a critical channel for specialties

Oncology combines some of the most life-changing therapeutic events with the most complex commercialization pathways. Rising costs of treatments simply add to the tension

As FDA makes progress on an active surveillance system, drug manufacturers and third-party drug safety vendors navigate their own set of challenges

But the global picture is sunny as most of the global market growth benefits the generic makers

Even as diagnosed (and “prediabetes”) cases rise worldwide, healthcare providers struggle with patients to control the course of the disease. New therapies—and new health services—are aiding in the battle

Trends in site selection, regional economic development and business expansion

A looming crisis in drug-resistant anti-infectives is not being met with a commensurate industry effort. Governments and industry are trying to cope

As hundreds of candidate drugs receive official “orphan” status, the Orphan Drug Act gets re-examined. Meanwhile, these drugs are driving the growth of specialty pharmacy

The 2010 PDMA Sharing Conference: Expanding Our Focus With More Learning Opportunities

Industry’s coming challenges will force dramatic change on how products are brought to market and businesses are sustained. Industry leaders have already started the process